NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

EMN26

NCT04564703: Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenance treatment after transplant.

Sponsor

European Myeloma Network

Collaborators

Celgene Corporation

Healt Data Specialists - HeaDS (CRO)

EMN Research Italy Impresa Sociale Srl

Location

Europe

---

ClinicalTrials.gov Identifier: NCT04564703

Official Title: Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients

First Posted: September 25, 2020

Click here for details on Clinicaltrials.gov

EMN26 - European Myeloma Network (myeloma-europe.org)

---

Drug: Iberdomide

---

Locations

Europe

France

Greece

Italy

Netherlands